Treating Hepatitis C: The big question no one is asking
from By Jason Poquette
If 2014 will be remembered for anything, pharmaceutically speaking, it will probably be for the impact of the new oral Hepatitis C therapies that entered the market. It began at the tail end of 2013 when Gilead introduced their $1,000-per-pill HCV cure known as Sovaldi (sofosbuvir). This drug, soon accompanied by a few others, has proved to be a game-changer in this space. The introduction of these new oral therapies has raised many questions, but there is one big question that few people seem to be asking.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063